Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06277154 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 24, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2024 to Feb 21, 2024
    • Site details revised
    • Collaborators expanded, about 5 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
Trial Details
NCT Number NCT06277154
Lead Sponsor HRYZ Biotech Co.
Collaborators: Sun Yat-Sen University Cancer Center
Conditions
(from sponsor)		 Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Fibrosarcoma +3 more
Related terms Desmoplastic Small Round Cell Tumor, Fibrosarcoma, Hemangiosarcoma, Histiocytoma, Malignant Fibrous, Leiomyosarcoma, Liposarcoma, Neurofibrosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Sarcoma, Synovial
Enrollment 148 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov